Btk Inhibitor Compound I Stability and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective inhibitors of Tec kinases, such as Bruton's tyrosine kinase (Btk), which are critical in B-cell and T-cell signaling, to address autoimmune disorders and other diseases, as existing inhibitors have limitations in off-target profiles and stability.
Innovation Solution
A novel compound, Compound I, and its solid forms are developed, exhibiting improved off-target profiles and stability, specifically inhibiting Btk in both in vitro and in vivo models, with desirable characteristics for treating diseases associated with Tec kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Btk inhibitors are used, then Btk enzymatic activity is inhibited, but off-target effects increase and stability decreases
Solution Approach 1:
The patent modifies the chemical structure of Btk inhibitors by changing parameters such as introducing a pyrimidine ring at the 6-position of the piperidine ring and adjusting substituents at specific positions. These structural parameter changes result in improved stability and reduced off-target effects while maintaining Btk inhibitory activity.
Solution Approach 2:
The invention creates composite molecular structures by combining multiple functional groups within a single inhibitor molecule. The compounds integrate a piperidine ring, pyrimidine ring, and various substituents into a unified molecular structure that simultaneously achieves stable binding to Btk and selective inhibition with reduced off-target effects.
2Adaptability or versatility
If Tec kinase inhibitors are developed, then autoimmune disorders are treated, but off-target profiles worsen
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at specific positions within the molecular structure. The pyrimidine ring is positioned at the 6-position of the piperidine ring, and specific substituents are placed at defined positions to create localized chemical features that enhance Btk selectivity while maintaining broader disease coverage.
Solution Approach 2:
The invention systematically modifies molecular parameters including the introduction of heterocyclic rings, adjustment of substituent types and positions, and optimization of molecular weight and lipophilicity. These parameter changes enable the inhibitors to effectively target Tec kinases for autoimmune disorder treatment while improving the off-target profile through enhanced selectivity.
Data Source
AI summary
The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.